Findings

What do systematic reviews say?

4,703 questions · 15,007 findings · 1,416 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,881 · 19.2%GRADE not reported 1,551 · 10.3%Very low 3,111 · 20.7%Low 3,881 · 25.9%Moderate 2,669 · 17.8%High 914 · 6.1%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Opioids vs Placebo, no intervention or usual care (with or without placebo)

Seizures To discharge · newborn infants with opioid withdrawal

1 finding from 1 review

Opioid treatment for opioid withdrawal in newborn infants 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Very low

Opioids vs Placebo, no intervention or usual care (with or without placebo)

Neonatal or infant mortality · newborn infants with opioid withdrawal

The review found no eligible studies for this question.

1 finding from 1 review

Opioid treatment for opioid withdrawal in newborn infants 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Opioids vs Placebo, no intervention or usual care (with or without placebo)

Neurodevelopmental disability · newborn infants with opioid withdrawal

The review found no eligible studies for this question.

1 finding from 1 review

Opioid treatment for opioid withdrawal in newborn infants 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Opioids vs Placebo, no intervention or usual care (with or without placebo)

Length of hospital stay · newborn infants with opioid withdrawal

1 finding from 1 review

Opioid treatment for opioid withdrawal in newborn infants 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Very low

Opioids vs Placebo, no intervention or usual care (with or without placebo)

Days treatment · newborn infants with opioid withdrawal

1 finding from 1 review

Opioid treatment for opioid withdrawal in newborn infants 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Very low

Opioids vs Placebo, no intervention or usual care (with or without placebo)

Adverse events (treatment related) To discharge · newborn infants with opioid withdrawal

The review found no eligible studies for this question.

1 finding from 1 review

Opioid treatment for opioid withdrawal in newborn infants 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Aspirin vs placebo

Graft thrombosis (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft

Aspirin showed no clear difference in graft thrombosis (28 days to 18 months) compared with placebo (low certainty).

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
OR 0.4 [0.07, 2.25]
3 studies · 175 participants
Low

Dipyridamole vs placebo

Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dipyridamole vs placebo

Complications (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous graft

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Low

Dipyridamole vs placebo

Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dipyridamole plus aspirin vs placebo

Graft thrombosis (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous graft

Dipyridamole plus aspirin showed no clear difference in graft thrombosis (up to 18 months) compared with placebo (moderate certainty).

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
OR 0.64 [0.16, 2.56]
1 study · 41 participants
Moderate

Dipyridamole plus aspirin vs placebo

Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dipyridamole plus aspirin vs placebo

Complications (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous graft

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Low

Dipyridamole plus aspirin vs placebo

Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Warfarin vs placebo

Graft thrombosis (up to 3 months) · people with ESRD receiving haemodialysis through an arteriovenous graft

Warfarin showed no clear difference in graft thrombosis (up to 37 months) compared with placebo (low certainty).

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
OR 1.76 [0.78, 3.99]
1 study · 107 participants
Low

Warfarin vs placebo

Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Warfarin vs placebo

Complications (up to 37 months) · people with ESRD receiving haemodialysis through an arteriovenous graft

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Low

Aspirin vs placebo

Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Warfarin vs placebo

Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fish oil vs placebo

Graft thrombosis (up to 12 months) · people with ESRD receiving haemodialysis through an arteriovenous graft

Fish oil showed no clear difference in graft thrombosis (up to 12 months) compared with placebo (low certainty).

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
OR 0.24 [0.03, 1.95]
2 studies · 220 participants
Low